SITC 2024 | 2141-V11: an anti-CD40 monoclonal antibody for tumor regression in patients with metastatic cancer
Juan Osorio, MD, Memorial Sloan Kettering Cancer Center, The Rockefeller University, New York, NY, introduces an in-human Phase I study (NCT04059588), which explored the efficacy and safety of 2141-V11, an anti-CD40 monoclonal antibody engineered to enhance the binding to the inhibitory receptor FcγRIIB, a critical interaction in the antitumor activity of antibodies. The study was developed to induce tumor regression whilst reducing drug-related toxicities in patients with metastatic cancer. This interview took place at the 39th Annual Meeting Society for Immunotherapy of Cancer 2024, Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
